May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Mice Lacking /ß GlcNAc–1–Phosphotransferase (GNPTA), a Gene Mutated in Patients With Mucolipidosis II, Exhibit Growth Retardation and Retinal Degeneration
Author Affiliations & Notes
  • C.M. Gelfman
    Lexicon Genetics Inc, The Woodlands, TX
    Ophthalmology,
  • T.M. Issa
    Lexicon Genetics Inc, The Woodlands, TX
    Ophthalmology,
  • M. Wiggins
    Lexicon Genetics Inc, The Woodlands, TX
    Ophthalmology,
  • H.A. Jones
    Lexicon Genetics Inc, The Woodlands, TX
    Ophthalmology,
  • P. Vogel
    Lexicon Genetics Inc, The Woodlands, TX
    Pathology,
  • D.S. Rice
    Lexicon Genetics Inc, The Woodlands, TX
    Ophthalmology,
  • Footnotes
    Commercial Relationships  C.M. Gelfman, Lexicon Genetics, E; T.M. Issa, Lexicon Genetics, E; M. Wiggins, Lexicon Genetics, E; H.A. Jones, Lexicon Genetics, E; P. Vogel, Lexicon Genetics, E; D.S. Rice, Lexicon Genetics, E.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5781. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.M. Gelfman, T.M. Issa, M. Wiggins, H.A. Jones, P. Vogel, D.S. Rice; Mice Lacking /ß GlcNAc–1–Phosphotransferase (GNPTA), a Gene Mutated in Patients With Mucolipidosis II, Exhibit Growth Retardation and Retinal Degeneration . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5781.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Mucolipidosis II and III (ML II; ML III) are lysosomal storage diseases characterized by a deficiency in the lysosomal enzyme GlcNAc–phosphotransferase, which adds phosphates to lysosomal enzymes thus allowing for their correct lysosomal targeting. Human patients with ML III have retinal disease, but in cases of the more clinically severe ML II, ophthalmic studies of human patients are limited. In this study, retinal function was assessed in mice lacking GNPTA, the gene mutated in patients with ML II.

Methods: : Mice deficient in GNPTA were generated from Omnibank, a sequence–tagged gene–trap library of >270,000 mouse embryonic stem cell clones as part of a large scale effort to knockout, phenotypically screen, and thereby validate pharmaceutically tractable genes for drug development. Routine diagnostics, expression analysis, histopathology, and ERG analysis were performed on mice lacking GNPTA.

Results: : Breedings between heterozygous GNPTA mice produced normal Mendelian ratios of homozygous mice. Heterozygous mice were phenotypically normal and in situ hybridization showed expression across the neural retina. At 8 weeks of age, retinas appeared histologically normal. At 12 weeks of age, severe retinal degeneration was observed, as measured by ONL thickness and TUNEL positive cells, and all photoreceptor function was ablated after 5 months as measured by ERG. Microscopic examination also revealed cytoplasmic alterations and hypertrophy of the acinar pancreas. Furthermore, the homozygous mutant mice exhibited signs of growth retardation, along with decreases in bone density measurements, features similar to those seen in patients with Mucolipodosis II.

Conclusions: : Mice deficient in GNPTA exhibited severe retinal degeneration. In addition, these mice exhibited additional features observed in patients with ML II, a lysosomal storage disease. Understanding underlying mechanisms of this gene in the eye will increase its therapeutic potential for treatment of retinal diseases.

Keywords: retinal degenerations: cell biology • transgenics/knock-outs • proteins encoded by disease genes 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×